china
end
caus
least
infect
feb
howev
specif
antivir
treatment
vaccin
current
recent
report
suggest
novel
cov
would
use
cell
entri
receptor
sarscov
report
gener
novel
recombin
protein
connect
extracellular
domain
human
fc
region
human
immunoglobulin
mutant
low
catalyt
activ
also
use
studi
fusion
protein
character
fusion
protein
high
affin
bind
receptorbind
domain
rbd
sarscov
exert
desir
pharmacolog
properti
moreov
fusion
protein
potent
neutral
sarscov
vitro
fusion
protein
exhibit
crossreact
coronavirus
could
potenti
applic
diagnosi
prophylaxi
treatment
authorfund
right
reserv
reus
allow
without
permiss
novel
coronaviru
emerg
wuhan
china
end
caus
least
infect
feb
howev
specif
antivir
treatment
vaccin
current
spike
protein
coronavirus
includ
coronaviru
caus
sever
acut
respiratori
syndrom
sar
associ
cellular
receptor
mediat
infect
target
cell
angiotensinconvert
enzym
carboxypeptidas
potent
degrad
angiotensin
ii
angiotensin
identifi
function
receptor
sarscov
potent
receptor
metallopeptidas
also
play
key
role
reninangiotensin
system
ra
key
player
hormon
cascad
play
central
role
homeostat
control
cardioren
action
earlier
research
exert
effect
pharmacodynam
studi
recombin
protect
sever
acut
lung
injuri
acut
ang
iiinduc
hypertens
mice
model
administr
also
show
advers
myocardi
remodel
attenu
ang
iiinduc
heart
hypertrophi
cardiac
dysfunct
well
renal
oxid
stress
inflamm
fibrosi
howev
human
mice
exhibit
fast
clearanc
rate
report
halflif
hour
pharmacokinet
studi
recent
fusion
protein
fc
fragment
show
organ
protect
acut
chronic
model
angiotensin
iidepend
hypertens
mice
interestingli
fusion
protein
also
show
longlast
effect
base
receptor
function
coronaviru
hypothesi
fusion
protein
may
neutral
potenti
coronaviru
especi
evalu
therapeut
potenti
fusion
protein
consist
extracellular
domain
human
link
fc
domain
human
construct
gener
fig
variant
hhnn
two
activesit
histidin
residu
alter
asparagin
also
use
studi
reduc
catalyt
activ
fusion
protein
contain
variant
term
express
purif
method
describ
previou
report
affin
fusion
protein
sarscov
rbd
rbd
determin
biacor
bind
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
assay
fig
fusion
protein
show
high
affin
rbd
moreov
fusion
protein
similar
denatur
temperatur
compar
fc
fusion
protein
tigitig
report
perviou
report
suggest
igglik
stabil
lowest
concentr
high
molecular
weight
low
molecular
weight
product
observ
week
storag
mgml
concentr
pharmacokinet
pk
paramet
fusion
protein
test
studi
mice
treat
separ
singl
intraven
dose
fusion
protein
serum
concentr
fusion
protein
determin
elisa
result
show
main
pk
paramet
tigitig
similar
mice
demonstr
high
stabil
fusion
protein
experiment
data
summar
tabl
identifi
fusion
protein
bind
rbd
high
affin
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
solubl
protein
extend
plasma
resid
time
improv
vivo
efficaci
gain
immunoreact
function
wide
use
modern
biopharmaceut
exampl
new
longact
form
recombin
coagul
factor
rfviiifc
rfixfc
recent
approv
clinic
treatment
hemophilia
b
requir
less
frequent
infus
tnf
receptor
fusion
protein
use
clinic
decad
unlik
blood
resid
enzym
coagul
factor
fulllength
endogen
transmembran
protein
anchor
cell
surfac
activ
fact
present
low
level
system
circul
therefor
one
safeti
concern
fusion
protein
may
system
cardiovascular
sideeffect
interestingli
one
recent
report
show
treatment
murin
fusion
protein
mice
show
evid
sideeffect
moreov
preliminari
studi
show
neutral
effect
remain
effici
two
activesit
histidin
modifi
asparagin
sum
data
investig
therapeut
potenti
base
strategi
could
use
alon
combin
base
molecular
mechan
block
fusion
protein
potenti
broad
neutral
activ
coronaviru
fusion
protein
could
also
use
diagnosi
research
reagent
develop
vaccin
inhibitor
recombin
fusion
plasmid
dna
sequenc
extracellular
domain
ecd
aa
ligat
fc
segment
human
mutat
gener
integr
dna
technolog
use
freestyl
express
system
invitrogen
express
fusion
protein
vector
detail
method
accord
previou
studi
fusion
protein
purifi
use
protein
sepharos
harvest
cell
cultur
supernat
tigitig
describ
perviou
report
serv
control
studi
concentr
puriti
fusion
protein
determin
measur
uv
absorb
wavelength
nm
polyacrylamid
gel
electrophoresi
respect
cov
rbd
prepar
previous
describ
use
previous
report
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
method
immobil
antihuman
fc
polyclon
antibodi
chip
ru
captur
fusion
protein
inject
cov
rbd
nm
blank
flow
cell
use
correct
bind
respons
surfac
plasmon
reson
spr
method
use
measur
monoval
bind
affin
fusion
protein
perform
kinet
analysi
use
l
model
simultan
fit
ka
kb
use
balbc
mice
determin
pharmacokinet
profil
fusion
protein
eightweekold
mice
administ
fusion
protein
dose
mgkg
bodi
weight
tail
vein
inject
mice
divid
group
correspond
day
day
blood
collect
septum
heparincontain
tube
centrifug
remov
blood
cell
obtain
plasma
sampl
serum
concentr
fusion
protein
determin
elisa
pseudovirus
contain
glycoprotein
variou
viru
defect
genom
express
luciferas
report
protein
prepar
assay
perform
describ
previous
quantit
cell
fusion
assay
base
galactosidas
report
gene
use
assess
neutral
activ
fusion
protein
describ
previous
cell
transfect
indic
cov
glycoprotein
gene
preincub
differ
fusion
protein
room
temperatur
min
mix
cell
transfect
ratio
incub
h
cell
lyse
gal
activ
measur
protein
concentr
fusion
use
calcul
defin
concentr
gal
activ
reduc
yl
md
declar
employe
pharchoic
therapeut
inc
